Hydrix Limited (ASX:HYD) has raised capital via a placement
October 2020 — Hydrix Limited has completed a capital raise with institutional and sophisticated investors. The capital will be used to bolster the company’s growth strategy and to extinguish outstanding secured debt.
Hydrix is a product innovation company providing product development services for clients in large addressable global markets, including medical and industrial, and connected cardiovascular technologies and services throughout the Asia Pacific region. With over 200 successfully designed products and solutions, Hydrix is recognized as one of the leading product development companies in Australia. It has three core business segments: services, medical and ventures. The company is underpinned by world-class product development expertise within Hydris Services and is now leveraging these skill sets to create and capture the value that it creates for its customers via Hydrix Medical and Hydrix Ventures.
Our role in the transaction
Oaklins’ team in Australia acted as co-manager in this transaction.
Talk to the deal team
Related deals
Life & Mobility has attracted investor Bolster Investment Partners
Life & Mobility, a leading developer and manufacturer of premium mobility and rehabilitation solutions, has welcomed Bolster Investment Partners as a new shareholder. The partnership provides Life & Mobility with a strong long-term partner to support the company’s next phase of growth, with a continued focus on product innovation, strengthening its leading market position and further international expansion. The company’s mission remains to enhance the mobility, independence and quality of life of end users through innovative, sustainable and circular mobility solutions designed for multiple life cycles.
Learn moreAsana Gruppe has sold selected outpatient service areas to Luzerner Kantonsspital
Luzerner Kantonsspital (LUKS) has acquired key parts of Asana Spital Menziken AG’s outpatient services from Asana Gruppe AG, including its ambulance service, primary care practice and ambulatory care center. The transaction supports the long-term continuity of local medical care in the Swiss Wynen and Seetal regions and ensures these services remain available close to patients’ homes.
Learn moreLaboratoires Herbolistique has received a majority investment from Yotta Capital Partners and co-investors
Laboratoires Herbolistique has received a majority investment from Yotta Capital Partners alongside co-investors Ouest Croissance, Sodero and CE IDF, with Bpifrance, Océans Participations and the management team reinvesting.
Learn more